XXSS
GENERIC MADRID TRANSACTION SENT TO IB
07/29/2026
Back to search
Official data from USPTO
VIVET THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
VIVET THERAPEUTICS
ST13
US500000079222595Class
5
Filing
79222595
Registration
5592503
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
07/29/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
02/03/2017
Registration date
10/30/2018
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/29/2025
Last transaction
07/29/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
FR
Examiner
MAZZELLA, BRANDY BARRETT
Current location
Historical data usage
Holders and representatives
Holders
V. T. (pessoa física)
Representatives
JANET G RICCIUTI JANET GILBERT RICCIUTI, PC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary products for the treatment of Wilson diseasemetabolic and inherited liver disordersviral and bacterial infectionsbodily conditions associated with impaired immunosystemssingle gene disordershemophiliablood disordersdiseases of the nervous systemneuro-degenerative disordersinflammatory and auto-immune diseases and disordersmetabolic system and endocrine system diseases and disorders ; immunosuppression pharmaceutical and veterinary products; sanitary preparations for medical purposes; Biological preparations for clinical medical use intended for gene therapy and cell therapy; Clinical medical reagents used for gene therapygenetic testing and diagnosis; Cellular preparations for medicalpharmaceutical or veterinary use for gene therapy and cell therapy; Gene therapy products for the treatment of Wilson diseasemetabolic and inherited liver disordersviral and bacterial infectionsbodily conditions associated with impaired immunosystemssingle gene disordershemophiliablood disordersdiseases of the nervous systemneuro-degenerative disordersinflammatory and auto-immune diseases and disordersmetabolic system and endocrine system diseases and disorders; Immunosuppression gene therapy products
Publications
History of USPTO decisions and trademark events.
40 publications found
XXCR
GENERIC MADRID TRANSACTION CREATED
07/29/2026
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/09/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
12/29/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
04/29/2025
71AG
REGISTERED-SEC.71 ACCEPTED
04/29/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/28/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/17/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/07/2025
ES71
TEAS SECTION 71 RECEIVED
10/30/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/16/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/30/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/14/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/26/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/01/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/08/2019
FIMP
FINAL DISPOSITION PROCESSED
02/08/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/30/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
10/30/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/18/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/14/2018
PUBO
PUBLISHED FOR OPPOSITION
08/14/2018
GPNX
NOTIFICATION PROCESSED BY IB
08/11/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/25/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/25/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/25/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/09/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/06/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/06/2018
RFNT
REFUSAL PROCESSED BY IB
01/27/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/08/2018
RFRR
REFUSAL PROCESSED BY MPU
01/08/2018
MAFR
APPLICATION FILING RECEIPT MAILED
12/19/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/16/2017
CNRT
NON-FINAL ACTION WRITTEN
12/15/2017
DOCK
ASSIGNED TO EXAMINER
12/15/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/15/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
12/12/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/07/2017
Continuous trademark protection
Get notified about every new filing that threatens VIVET THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.